{"cells":[{"cell_type":"code","source":["dbutils.fs.ls(\"/FileStore/tables/clinicaltrial_2021_csv.gz\")"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"7296e7f2-a016-4f9f-a25e-2ece89ecb889"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[1]: [FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021_csv.gz', name='clinicaltrial_2021_csv.gz', size=11921810, modificationTime=1647433652000)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[1]: [FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021_csv.gz', name='clinicaltrial_2021_csv.gz', size=11921810, modificationTime=1647433652000)]"]}}],"execution_count":0},{"cell_type":"code","source":["dbutils.fs.cp(\"/FileStore/tables/clinicaltrial_2021_csv.gz\", \"file:/tmp\")"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"036f04f3-4761-4729-b27d-6dc6c6737f5c"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[2]: True","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[2]: True"]}}],"execution_count":0},{"cell_type":"code","source":["%sh\ngunzip /tmp/clinicaltrial_2021_csv.gz\nls /tmp"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"22ff3af9-5633-4538-89c0-08dfabc7c004"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Rserv\nRtmpAJSxUn\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2021_csv\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\nipykernel-connection-ReplId-4dcc4-325cb-f6e26.json\nipykernel-connection-ReplId-5feaf-1f7c9-5114d-0.json\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-apache2.service-Tj9Npj\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-ntp.service-sWqKwg\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-systemd-logind.service-2ifxpf\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-systemd-resolved.service-vzPB1e\ntmp.hVE5WUPxTv\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Rserv\nRtmpAJSxUn\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2021_csv\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\nipykernel-connection-ReplId-4dcc4-325cb-f6e26.json\nipykernel-connection-ReplId-5feaf-1f7c9-5114d-0.json\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-apache2.service-Tj9Npj\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-ntp.service-sWqKwg\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-systemd-logind.service-2ifxpf\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-systemd-resolved.service-vzPB1e\ntmp.hVE5WUPxTv\n"]}}],"execution_count":0},{"cell_type":"code","source":["%sh\nmv  /tmp/clinicaltrial_2021_csv /tmp/clinicaltrial_2021.csv\nls  /tmp"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"45adab3a-d03f-45b7-a5cc-127e3d48279e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Rserv\nRtmpAJSxUn\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2021.csv\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\nipykernel-connection-ReplId-4dcc4-325cb-f6e26.json\nipykernel-connection-ReplId-5feaf-1f7c9-5114d-0.json\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-apache2.service-Tj9Npj\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-ntp.service-sWqKwg\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-systemd-logind.service-2ifxpf\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-systemd-resolved.service-vzPB1e\ntmp.hVE5WUPxTv\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Rserv\nRtmpAJSxUn\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2021.csv\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\nipykernel-connection-ReplId-4dcc4-325cb-f6e26.json\nipykernel-connection-ReplId-5feaf-1f7c9-5114d-0.json\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-apache2.service-Tj9Npj\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-ntp.service-sWqKwg\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-systemd-logind.service-2ifxpf\nsystemd-private-fe53b4ca92414eddbd51f872fe674a82-systemd-resolved.service-vzPB1e\ntmp.hVE5WUPxTv\n"]}}],"execution_count":0},{"cell_type":"code","source":["dbutils.fs.mv(\"file:/tmp/clinicaltrial_2021.csv\", \"/FileStore/tables/\", True)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"50a26075-0034-42ab-a8c1-8c90a04e3e90"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[5]: True","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[5]: True"]}}],"execution_count":0},{"cell_type":"markdown","source":["CREATE MY RDD"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"eec5a0e7-7c32-44f7-9639-306d7134c4f6"}}},{"cell_type":"code","source":["my1stRDD= sc.textFile(\"DBFS:/FileStore/tables/clinicaltrial_2021.csv\")"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"93456114-80e5-4e2d-8bb8-74378c13d6e1"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["my1stRDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"2ce2007f-b774-4ca2-87ef-fae35428bc22"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[7]: ['Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions',\n 'NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[7]: ['Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions',\n 'NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|']"]}}],"execution_count":0},{"cell_type":"code","source":["headername = my1stRDD.first()\nmy2ndRDD = my1stRDD.filter(lambda line: line!= headername)\nmy2ndRDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"098029a5-786c-4d40-a8aa-610d66bcb356"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[8]: ['NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|',\n 'NCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[8]: ['NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|',\n 'NCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|']"]}}],"execution_count":0},{"cell_type":"markdown","source":["SPLIT MY RDD"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"d7277ac5-7be7-4496-9cc7-e90c29f324db"}}},{"cell_type":"code","source":["mysplitRDD = my2ndRDD.map(lambda c: (c.split (\"|\")))\nmysplitRDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"32640e43-5bff-44ff-b196-393cd5bcf21f"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[9]: [['NCT02758028',\n  'The University of Hong Kong',\n  'Recruiting',\n  'Aug 2005',\n  'Nov 2021',\n  'Interventional',\n  'Apr 2016',\n  '',\n  ''],\n ['NCT02751957',\n  'Duke University',\n  'Completed',\n  'Jul 2016',\n  'Jul 2020',\n  'Interventional',\n  'Apr 2016',\n  'Autistic Disorder,Autism Spectrum Disorder',\n  ''],\n ['NCT02758483',\n  'Universidade Federal do Rio de Janeiro',\n  'Completed',\n  'Mar 2017',\n  'Jan 2018',\n  'Interventional',\n  'Apr 2016',\n  'Diabetes Mellitus',\n  ''],\n ['NCT02759848',\n  'Istanbul Medeniyet University',\n  'Completed',\n  'Jan 2012',\n  'Dec 2014',\n  'Observational',\n  'May 2016',\n  'Tuberculosis,Lung Diseases,Pulmonary Disease',\n  ''],\n ['NCT02758860',\n  'University of Roma La Sapienza',\n  'Active, not recruiting',\n  'Jun 2016',\n  'Sep 2020',\n  'Observational [Patient Registry]',\n  'Apr 2016',\n  'Diverticular Diseases,Diverticulum,Diverticulosis',\n  '']]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[9]: [['NCT02758028',\n  'The University of Hong Kong',\n  'Recruiting',\n  'Aug 2005',\n  'Nov 2021',\n  'Interventional',\n  'Apr 2016',\n  '',\n  ''],\n ['NCT02751957',\n  'Duke University',\n  'Completed',\n  'Jul 2016',\n  'Jul 2020',\n  'Interventional',\n  'Apr 2016',\n  'Autistic Disorder,Autism Spectrum Disorder',\n  ''],\n ['NCT02758483',\n  'Universidade Federal do Rio de Janeiro',\n  'Completed',\n  'Mar 2017',\n  'Jan 2018',\n  'Interventional',\n  'Apr 2016',\n  'Diabetes Mellitus',\n  ''],\n ['NCT02759848',\n  'Istanbul Medeniyet University',\n  'Completed',\n  'Jan 2012',\n  'Dec 2014',\n  'Observational',\n  'May 2016',\n  'Tuberculosis,Lung Diseases,Pulmonary Disease',\n  ''],\n ['NCT02758860',\n  'University of Roma La Sapienza',\n  'Active, not recruiting',\n  'Jun 2016',\n  'Sep 2020',\n  'Observational [Patient Registry]',\n  'Apr 2016',\n  'Diverticular Diseases,Diverticulum,Diverticulosis',\n  '']]"]}}],"execution_count":0},{"cell_type":"markdown","source":["Question 1"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"14f0d095-2f23-4539-8fd3-dfb5778ec2f8"}}},{"cell_type":"code","source":["my2ndRDD.count()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"ba33ee4a-5d2e-48dd-97d2-b2d47afcc52e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[10]: 387261","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[10]: 387261"]}}],"execution_count":0},{"cell_type":"markdown","source":["Question 2"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"4ccbf564-245b-4d4f-acab-fbda1a0677e4"}}},{"cell_type":"code","source":["typesRDD= mysplitRDD.map(lambda c: (c[5],int(1)))\ntypesRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"ad8362b7-3cee-40fe-84cc-7cc44684c4f5"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[11]: [('Interventional', 1),\n ('Interventional', 1),\n ('Interventional', 1),\n ('Observational', 1),\n ('Observational [Patient Registry]', 1),\n ('Interventional', 1),\n ('Observational [Patient Registry]', 1),\n ('Interventional', 1),\n ('Interventional', 1),\n ('Interventional', 1)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[11]: [('Interventional', 1),\n ('Interventional', 1),\n ('Interventional', 1),\n ('Observational', 1),\n ('Observational [Patient Registry]', 1),\n ('Interventional', 1),\n ('Observational [Patient Registry]', 1),\n ('Interventional', 1),\n ('Interventional', 1),\n ('Interventional', 1)]"]}}],"execution_count":0},{"cell_type":"code","source":["types2RDD=typesRDD.reduceByKey(lambda c, d: c+d)\ntypes2RDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3db3f061-4146-4524-9c48-52fc55d55e45"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[12]: [('Observational', 77540),\n ('Observational [Patient Registry]', 8180),\n ('Interventional', 301472),\n ('Expanded Access', 69)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[12]: [('Observational', 77540),\n ('Observational [Patient Registry]', 8180),\n ('Interventional', 301472),\n ('Expanded Access', 69)]"]}}],"execution_count":0},{"cell_type":"code","source":["types3RDD= types2RDD.sortBy(lambda c: c[1], ascending=False)\ntypes3RDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"bae0833e-2620-4d1f-9a36-28032be785fd"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[13]: [('Interventional', 301472),\n ('Observational', 77540),\n ('Observational [Patient Registry]', 8180),\n ('Expanded Access', 69)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[13]: [('Interventional', 301472),\n ('Observational', 77540),\n ('Observational [Patient Registry]', 8180),\n ('Expanded Access', 69)]"]}}],"execution_count":0},{"cell_type":"code","source":["def toCSVLine(output):\n    return ' '.join(str(d) for d in output)\nfreshRDD=types3RDD.map(toCSVLine)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"72a156a2-7bd5-4687-a8de-3bcb1fdc230d"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["freshRDD.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"ed7a2bb7-c777-4570-8125-45681bc26156"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[15]: ['Interventional 301472',\n 'Observational 77540',\n 'Observational [Patient Registry] 8180',\n 'Expanded Access 69']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[15]: ['Interventional 301472',\n 'Observational 77540',\n 'Observational [Patient Registry] 8180',\n 'Expanded Access 69']"]}}],"execution_count":0},{"cell_type":"code","source":["for c in freshRDD.collect():\n    print (c)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"01ddaa2b-81f4-463e-82c3-eb9a18f19c9c"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Interventional 301472\nObservational 77540\nObservational [Patient Registry] 8180\nExpanded Access 69\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Interventional 301472\nObservational 77540\nObservational [Patient Registry] 8180\nExpanded Access 69\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["QUESTION 3"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"85cdba0f-5b40-4910-8524-5169a0e98c4d"}}},{"cell_type":"code","source":["myconditionsRDD= mysplitRDD.map(lambda c: (c[7]))\nmyconditionsRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"103fd7cf-c4a1-48e0-9570-09fe4370dc4e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[17]: ['',\n 'Autistic Disorder,Autism Spectrum Disorder',\n 'Diabetes Mellitus',\n 'Tuberculosis,Lung Diseases,Pulmonary Disease',\n 'Diverticular Diseases,Diverticulum,Diverticulosis',\n 'Asthma',\n 'Hypoventilation',\n 'Lymphoma',\n '',\n 'Myositis']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[17]: ['',\n 'Autistic Disorder,Autism Spectrum Disorder',\n 'Diabetes Mellitus',\n 'Tuberculosis,Lung Diseases,Pulmonary Disease',\n 'Diverticular Diseases,Diverticulum,Diverticulosis',\n 'Asthma',\n 'Hypoventilation',\n 'Lymphoma',\n '',\n 'Myositis']"]}}],"execution_count":0},{"cell_type":"code","source":["mysplitconditionsRDD= myconditionsRDD.flatMap(lambda c: (c.split(\",\")))\nmysplitconditionsRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"2cd0d60a-a4db-482a-b344-3936690f75d2"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[18]: ['',\n 'Autistic Disorder',\n 'Autism Spectrum Disorder',\n 'Diabetes Mellitus',\n 'Tuberculosis',\n 'Lung Diseases',\n 'Pulmonary Disease',\n 'Diverticular Diseases',\n 'Diverticulum',\n 'Diverticulosis']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[18]: ['',\n 'Autistic Disorder',\n 'Autism Spectrum Disorder',\n 'Diabetes Mellitus',\n 'Tuberculosis',\n 'Lung Diseases',\n 'Pulmonary Disease',\n 'Diverticular Diseases',\n 'Diverticulum',\n 'Diverticulosis']"]}}],"execution_count":0},{"cell_type":"code","source":["Space= ['']\nmyfilteredRDD=mysplitconditionsRDD.filter(lambda c: c not in Space)\nmyfilteredRDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"b18cd8bb-8d35-4e46-8a1e-4206a6bc0ddd"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[19]: ['Autistic Disorder',\n 'Autism Spectrum Disorder',\n 'Diabetes Mellitus',\n 'Tuberculosis',\n 'Lung Diseases']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[19]: ['Autistic Disorder',\n 'Autism Spectrum Disorder',\n 'Diabetes Mellitus',\n 'Tuberculosis',\n 'Lung Diseases']"]}}],"execution_count":0},{"cell_type":"code","source":["myfiltered2RDD= myfilteredRDD.map(lambda c:(c,1))\nmyfiltered2RDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"46551bdd-4738-4c2b-a823-d27f57f1e705"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[20]: [('Autistic Disorder', 1),\n ('Autism Spectrum Disorder', 1),\n ('Diabetes Mellitus', 1),\n ('Tuberculosis', 1),\n ('Lung Diseases', 1),\n ('Pulmonary Disease', 1),\n ('Diverticular Diseases', 1),\n ('Diverticulum', 1),\n ('Diverticulosis', 1),\n ('Asthma', 1)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[20]: [('Autistic Disorder', 1),\n ('Autism Spectrum Disorder', 1),\n ('Diabetes Mellitus', 1),\n ('Tuberculosis', 1),\n ('Lung Diseases', 1),\n ('Pulmonary Disease', 1),\n ('Diverticular Diseases', 1),\n ('Diverticulum', 1),\n ('Diverticulosis', 1),\n ('Asthma', 1)]"]}}],"execution_count":0},{"cell_type":"code","source":["myfiltered3RDD= myfiltered2RDD.reduceByKey(lambda c, d: c+d)\nmyfiltered3RDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"556270a5-68bd-4c24-bc71-5f3651cfbbe1"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[21]: [('Autistic Disorder', 867),\n ('Autism Spectrum Disorder', 880),\n ('Tuberculosis', 1118),\n ('Diverticular Diseases', 65),\n ('Diverticulosis', 18),\n ('Asthma', 3089),\n ('Lymphoma', 5395),\n ('Myositis', 108),\n ('Stomach Ulcer', 90),\n ('Cholelithiasis', 180)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[21]: [('Autistic Disorder', 867),\n ('Autism Spectrum Disorder', 880),\n ('Tuberculosis', 1118),\n ('Diverticular Diseases', 65),\n ('Diverticulosis', 18),\n ('Asthma', 3089),\n ('Lymphoma', 5395),\n ('Myositis', 108),\n ('Stomach Ulcer', 90),\n ('Cholelithiasis', 180)]"]}}],"execution_count":0},{"cell_type":"code","source":["lastfilteredRDD= myfiltered3RDD.sortBy(lambda c: c[1], ascending=False)\nlastfilteredRDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"bf39fad6-89a7-4e3b-8537-62fc8894281e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[22]: [('Carcinoma', 13389),\n ('Diabetes Mellitus', 11080),\n ('Neoplasms', 9371),\n ('Breast Neoplasms', 8640),\n ('Syndrome', 8032)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[22]: [('Carcinoma', 13389),\n ('Diabetes Mellitus', 11080),\n ('Neoplasms', 9371),\n ('Breast Neoplasms', 8640),\n ('Syndrome', 8032)]"]}}],"execution_count":0},{"cell_type":"code","source":["def toCSVLine(output):\n    return ' '.join(str(f) for f in output)\nlastfiltered2RDD=lastfilteredRDD.map(toCSVLine)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"1dd96f20-4782-43d8-9acd-aa08d901e8bc"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["lastfiltered2RDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"da91bee8-2361-4c5f-8231-31c98672dc7f"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[24]: ['Carcinoma 13389',\n 'Diabetes Mellitus 11080',\n 'Neoplasms 9371',\n 'Breast Neoplasms 8640',\n 'Syndrome 8032']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[24]: ['Carcinoma 13389',\n 'Diabetes Mellitus 11080',\n 'Neoplasms 9371',\n 'Breast Neoplasms 8640',\n 'Syndrome 8032']"]}}],"execution_count":0},{"cell_type":"code","source":["for c in lastfiltered2RDD.take(5):\n    print (c)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"4d21cf24-afe7-4057-be73-3ed5e8787dae"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Carcinoma 13389\nDiabetes Mellitus 11080\nNeoplasms 9371\nBreast Neoplasms 8640\nSyndrome 8032\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Carcinoma 13389\nDiabetes Mellitus 11080\nNeoplasms 9371\nBreast Neoplasms 8640\nSyndrome 8032\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["QUESTION 4"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"cbfe0090-0654-4b79-bafc-69dadd6295ad"}}},{"cell_type":"markdown","source":["CREATE MESH RDD"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"49ff8049-85de-4eba-b8d7-05410c955968"}}},{"cell_type":"code","source":["mymeshRDD= sc.textFile(\"DBFS:/FileStore/tables/mesh.csv\")\nmymeshRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"de361010-52b7-44d2-b5f7-520c306fcc78"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[26]: ['term,tree',\n 'Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800',\n 'Temefos,D02.886.300.692.800',\n 'Abate,D02.705.400.625.800',\n 'Abate,D02.705.539.345.800',\n 'Abate,D02.886.300.692.800',\n 'Difos,D02.705.400.625.800']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[26]: ['term,tree',\n 'Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800',\n 'Temefos,D02.886.300.692.800',\n 'Abate,D02.705.400.625.800',\n 'Abate,D02.705.539.345.800',\n 'Abate,D02.886.300.692.800',\n 'Difos,D02.705.400.625.800']"]}}],"execution_count":0},{"cell_type":"code","source":["header = mymeshRDD.first()\nnoheaderRDD = mymeshRDD.filter(lambda line: line!= header)\nnoheaderRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"62c0a081-7ca8-4420-8f66-d9a65cbe409e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[27]: ['Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800',\n 'Temefos,D02.886.300.692.800',\n 'Abate,D02.705.400.625.800',\n 'Abate,D02.705.539.345.800',\n 'Abate,D02.886.300.692.800',\n 'Difos,D02.705.400.625.800',\n 'Difos,D02.705.539.345.800']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[27]: ['Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800',\n 'Temefos,D02.886.300.692.800',\n 'Abate,D02.705.400.625.800',\n 'Abate,D02.705.539.345.800',\n 'Abate,D02.886.300.692.800',\n 'Difos,D02.705.400.625.800',\n 'Difos,D02.705.539.345.800']"]}}],"execution_count":0},{"cell_type":"code","source":["splitedmeshRDD=noheaderRDD.map(lambda row: (row.split(\",\")))\nsplitedmeshRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"45f6601a-b046-46fa-a940-2dc411612608"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[28]: [['Calcimycin', 'D03.633.100.221.173'],\n ['A-23187', 'D03.633.100.221.173'],\n ['Temefos', 'D02.705.400.625.800'],\n ['Temefos', 'D02.705.539.345.800'],\n ['Temefos', 'D02.886.300.692.800'],\n ['Abate', 'D02.705.400.625.800'],\n ['Abate', 'D02.705.539.345.800'],\n ['Abate', 'D02.886.300.692.800'],\n ['Difos', 'D02.705.400.625.800'],\n ['Difos', 'D02.705.539.345.800']]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[28]: [['Calcimycin', 'D03.633.100.221.173'],\n ['A-23187', 'D03.633.100.221.173'],\n ['Temefos', 'D02.705.400.625.800'],\n ['Temefos', 'D02.705.539.345.800'],\n ['Temefos', 'D02.886.300.692.800'],\n ['Abate', 'D02.705.400.625.800'],\n ['Abate', 'D02.705.539.345.800'],\n ['Abate', 'D02.886.300.692.800'],\n ['Difos', 'D02.705.400.625.800'],\n ['Difos', 'D02.705.539.345.800']]"]}}],"execution_count":0},{"cell_type":"code","source":["joinedmeshcli=lastfilteredRDD.join(splitedmeshRDD)\njoinedmeshcli.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"0f69834b-11f4-4f26-aa6c-8802a456a11d"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[29]: [('Syndrome', (8032, 'C23.550.288.500')),\n ('Lymphoma', (5395, 'C04.557.386')),\n ('Lymphoma', (5395, 'C15.604.515.569')),\n ('Lymphoma', (5395, 'C20.683.515.761')),\n ('Infections', (5323, 'C01'))]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[29]: [('Syndrome', (8032, 'C23.550.288.500')),\n ('Lymphoma', (5395, 'C04.557.386')),\n ('Lymphoma', (5395, 'C15.604.515.569')),\n ('Lymphoma', (5395, 'C20.683.515.761')),\n ('Infections', (5323, 'C01'))]"]}}],"execution_count":0},{"cell_type":"code","source":["mapjoined=joinedmeshcli.map(lambda c: (c[1]))\\\n.map(lambda c: (c[1],c[0]))\\\n.map(lambda c: (c[0].split('.')[0],c[1]))\\\n.reduceByKey(lambda c,d: c+d )\\\n.sortBy(lambda c: c[1], ascending=False)\nmapjoined.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"cc9e3453-3bab-4bfc-a001-53bc3c54456c"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[30]: [('C04', 143994),\n ('C23', 136079),\n ('C01', 106674),\n ('C14', 94523),\n ('C10', 92310),\n ('C06', 85646),\n ('C08', 70720),\n ('C13', 42599),\n ('C18', 41276),\n ('C12', 40161)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[30]: [('C04', 143994),\n ('C23', 136079),\n ('C01', 106674),\n ('C14', 94523),\n ('C10', 92310),\n ('C06', 85646),\n ('C08', 70720),\n ('C13', 42599),\n ('C18', 41276),\n ('C12', 40161)]"]}}],"execution_count":0},{"cell_type":"markdown","source":["QUESTION 5"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c77261c4-e1bb-4c40-8a38-255c114520e1"}}},{"cell_type":"code","source":["mypharmaRDD= sc.textFile(\"DBFS:/FileStore/tables/pharma.csv\")\nmypharmaRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"4c017340-6104-4629-bc08-ba353e295dbf"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[31]: ['\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"',\n '\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"',\n '\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"',\n '\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"',\n '\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"',\n '\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[31]: ['\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"',\n '\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"',\n '\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"',\n '\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"',\n '\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"',\n '\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"']"]}}],"execution_count":0},{"cell_type":"code","source":["header = mypharmaRDD.first()\nnoheaderpharmaRDD = mypharmaRDD.filter(lambda line: line!= header)\nnoheaderpharmaRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"46440074-ba92-4f72-9ad9-c713a21d1f97"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[32]: ['\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"',\n '\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"',\n '\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"',\n '\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"',\n '\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"',\n '\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[32]: ['\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"',\n '\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"',\n '\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"',\n '\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"',\n '\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"',\n '\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"']"]}}],"execution_count":0},{"cell_type":"code","source":["splitedpharmaRDD= noheaderpharmaRDD.map(lambda row:(row.split (\",\",)))\nsplitedpharmaRDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"a73699a6-d276-4fa7-b558-71e4c1138c58"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[33]: [['\"Abbott Laboratories\"',\n  '\"Abbott Laboratories\"',\n  '\"$5',\n  '475',\n  '000\"',\n  '\"$0\"',\n  '\"$5',\n  '475',\n  '000\"',\n  '\"2013\"',\n  '\"20131227\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"kickbacks and bribery\"',\n  '\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid',\n  ' biliary and peripheral vascular products.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\"',\n  '\"\"'],\n ['\"Abbott Laboratories Inc.\"',\n  '\"AbbVie\"',\n  '\"$1',\n  '500',\n  '000',\n  '000\"',\n  '\"$0\"',\n  '\"$1',\n  '500',\n  '000',\n  '000\"',\n  '\"2012\"',\n  '\"20120507\"',\n  '\"healthcare-related offenses\"',\n  '\"off-label or unapproved promotion of medical products\"',\n  '\"\"',\n  '\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Food and Drug Administration referral to the Justice Department\"',\n  '\"civil and criminal\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABBV\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\"',\n  '\"\"'],\n ['\"Abbott Laboratories Inc.\"',\n  '\"AbbVie\"',\n  '\"$126',\n  '500',\n  '000\"',\n  '\"$0\"',\n  '\"$126',\n  '500',\n  '000\"',\n  '\"2010\"',\n  '\"20101207\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"\"',\n  '\"Abbott Laboratories Inc.',\n  ' B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations',\n  ' that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABBV\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\"',\n  '\"\"'],\n ['\"Abbott Laboratories Puerto Rico',\n  ' Inc.\"',\n  '\"Abbott Laboratories\"',\n  '\"$49',\n  '045\"',\n  '\"$0\"',\n  '\"$49',\n  '045\"',\n  '\"2009\"',\n  '\"20090305\"',\n  '\"employment-related offenses\"',\n  '\"wage and hour violation\"',\n  '\"Fair Labor Standards Act\"',\n  '\"\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Labor Department Wage and Hour Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"1527129\"',\n  '\"\"',\n  '\"\"',\n  '\"Puerto Rico\"',\n  '\"San Juan\"',\n  '\"\"',\n  '\"\"',\n  '\"423450\"',\n  '\"423450: Medical',\n  ' Dental',\n  ' and Hospital Equipment and Supplies Merchant Wholesalers\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"March 7',\n  ' 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\"',\n  '\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division',\n  ' which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank',\n  ' in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"'],\n ['\"Acclarent Inc.\"',\n  '\"Johnson & Johnson\"',\n  '\"$18',\n  '000',\n  '000\"',\n  '\"$0\"',\n  '\"$18',\n  '000',\n  '000\"',\n  '\"2016\"',\n  '\"20160722\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"\"',\n  '\"California-based medical device manufacturer Acclarent Inc.',\n  ' a subsidiary of Johnson & Johnson',\n  ' agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"New Jersey\"',\n  '\"publicly traded\"',\n  '\"JNJ\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\"',\n  '\"\"']]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[33]: [['\"Abbott Laboratories\"',\n  '\"Abbott Laboratories\"',\n  '\"$5',\n  '475',\n  '000\"',\n  '\"$0\"',\n  '\"$5',\n  '475',\n  '000\"',\n  '\"2013\"',\n  '\"20131227\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"kickbacks and bribery\"',\n  '\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid',\n  ' biliary and peripheral vascular products.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\"',\n  '\"\"'],\n ['\"Abbott Laboratories Inc.\"',\n  '\"AbbVie\"',\n  '\"$1',\n  '500',\n  '000',\n  '000\"',\n  '\"$0\"',\n  '\"$1',\n  '500',\n  '000',\n  '000\"',\n  '\"2012\"',\n  '\"20120507\"',\n  '\"healthcare-related offenses\"',\n  '\"off-label or unapproved promotion of medical products\"',\n  '\"\"',\n  '\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Food and Drug Administration referral to the Justice Department\"',\n  '\"civil and criminal\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABBV\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\"',\n  '\"\"'],\n ['\"Abbott Laboratories Inc.\"',\n  '\"AbbVie\"',\n  '\"$126',\n  '500',\n  '000\"',\n  '\"$0\"',\n  '\"$126',\n  '500',\n  '000\"',\n  '\"2010\"',\n  '\"20101207\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"\"',\n  '\"Abbott Laboratories Inc.',\n  ' B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations',\n  ' that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABBV\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\"',\n  '\"\"'],\n ['\"Abbott Laboratories Puerto Rico',\n  ' Inc.\"',\n  '\"Abbott Laboratories\"',\n  '\"$49',\n  '045\"',\n  '\"$0\"',\n  '\"$49',\n  '045\"',\n  '\"2009\"',\n  '\"20090305\"',\n  '\"employment-related offenses\"',\n  '\"wage and hour violation\"',\n  '\"Fair Labor Standards Act\"',\n  '\"\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Labor Department Wage and Hour Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"1527129\"',\n  '\"\"',\n  '\"\"',\n  '\"Puerto Rico\"',\n  '\"San Juan\"',\n  '\"\"',\n  '\"\"',\n  '\"423450\"',\n  '\"423450: Medical',\n  ' Dental',\n  ' and Hospital Equipment and Supplies Merchant Wholesalers\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"March 7',\n  ' 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\"',\n  '\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division',\n  ' which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank',\n  ' in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"'],\n ['\"Acclarent Inc.\"',\n  '\"Johnson & Johnson\"',\n  '\"$18',\n  '000',\n  '000\"',\n  '\"$0\"',\n  '\"$18',\n  '000',\n  '000\"',\n  '\"2016\"',\n  '\"20160722\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"\"',\n  '\"California-based medical device manufacturer Acclarent Inc.',\n  ' a subsidiary of Johnson & Johnson',\n  ' agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"New Jersey\"',\n  '\"publicly traded\"',\n  '\"JNJ\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\"',\n  '\"\"']]"]}}],"execution_count":0},{"cell_type":"code","source":["newpharma= noheaderpharmaRDD.map(lambda line: line.replace('\"','').split(\",\") [1])\\\n.map(lambda c:(c,1))\\\n.reduceByKey(lambda c,d: c+d)\nnewpharma.take(20)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c58605e5-0bfd-455a-a376-fb9cac8e27f1"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[34]: [('Abbott Laboratories', 26),\n ('AbbVie', 38),\n (' LLC', 26),\n ('AstraZeneca', 22),\n ('Sanofi', 24),\n ('AVEO Pharmaceuticals', 1),\n ('Bausch Health', 11),\n ('GlaxoSmithKline', 31),\n ('Teva Pharmaceutical Industries', 36),\n ('Merck', 64),\n ('Novartis', 34),\n ('Daiichi Sankyo', 5),\n ('Eisai', 7),\n ('KV Pharmaceutical', 7),\n (\" INC. EMPLOYEES' 401(K) SAVINGS PLAN\", 1),\n ('Novo Holdings A/S', 8),\n (' INC.', 38),\n ('Sun Pharmaceuticals', 4),\n (' S.A.', 1),\n ('Takeda Pharmaceutical', 17)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[34]: [('Abbott Laboratories', 26),\n ('AbbVie', 38),\n (' LLC', 26),\n ('AstraZeneca', 22),\n ('Sanofi', 24),\n ('AVEO Pharmaceuticals', 1),\n ('Bausch Health', 11),\n ('GlaxoSmithKline', 31),\n ('Teva Pharmaceutical Industries', 36),\n ('Merck', 64),\n ('Novartis', 34),\n ('Daiichi Sankyo', 5),\n ('Eisai', 7),\n ('KV Pharmaceutical', 7),\n (\" INC. EMPLOYEES' 401(K) SAVINGS PLAN\", 1),\n ('Novo Holdings A/S', 8),\n (' INC.', 38),\n ('Sun Pharmaceuticals', 4),\n (' S.A.', 1),\n ('Takeda Pharmaceutical', 17)]"]}}],"execution_count":0},{"cell_type":"code","source":["mapRDD= mysplitRDD.map(lambda c: (c[1]))\\\n.map(lambda c: (c,1))\\\n.reduceByKey(lambda c,d: c+d)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"beca8c37-6113-4ad2-a3f8-3f0003b9e9fb"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["mapRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"b6ff9233-47b1-43ad-92d8-7537725193c5"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[36]: [('The University of Hong Kong', 757),\n ('Universidade Federal do Rio de Janeiro', 103),\n ('University of Roma La Sapienza', 289),\n ('Ankara University', 107),\n ('Ruijin Hospital', 200),\n ('Washington University School of Medicine', 1374),\n ('Orphazyme', 7),\n ('Novo Nordisk A/S', 1081),\n ('Bulent Ecevit University', 31),\n ('Institut für Pharmakologie und Präventive Medizin', 24)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[36]: [('The University of Hong Kong', 757),\n ('Universidade Federal do Rio de Janeiro', 103),\n ('University of Roma La Sapienza', 289),\n ('Ankara University', 107),\n ('Ruijin Hospital', 200),\n ('Washington University School of Medicine', 1374),\n ('Orphazyme', 7),\n ('Novo Nordisk A/S', 1081),\n ('Bulent Ecevit University', 31),\n ('Institut für Pharmakologie und Präventive Medizin', 24)]"]}}],"execution_count":0},{"cell_type":"code","source":["joinedclin= mapRDD.subtractByKey(newpharma)\\\n.sortBy(lambda c: c[1], ascending=False)\njoinedclin.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5bdd7e62-c153-450e-9b7b-6d74cf3fce02"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[37]: [('National Cancer Institute (NCI)', 3218),\n ('M.D. Anderson Cancer Center', 2414),\n ('Assistance Publique - Hôpitaux de Paris', 2369),\n ('Mayo Clinic', 2300),\n ('Merck Sharp & Dohme Corp.', 2243),\n ('Assiut University', 2154),\n ('Novartis Pharmaceuticals', 2088),\n ('Massachusetts General Hospital', 1971),\n ('Cairo University', 1928),\n ('Hoffmann-La Roche', 1828)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[37]: [('National Cancer Institute (NCI)', 3218),\n ('M.D. Anderson Cancer Center', 2414),\n ('Assistance Publique - Hôpitaux de Paris', 2369),\n ('Mayo Clinic', 2300),\n ('Merck Sharp & Dohme Corp.', 2243),\n ('Assiut University', 2154),\n ('Novartis Pharmaceuticals', 2088),\n ('Massachusetts General Hospital', 1971),\n ('Cairo University', 1928),\n ('Hoffmann-La Roche', 1828)]"]}}],"execution_count":0},{"cell_type":"code","source":["def toCSVLine(field):\n    return \" \".join(str(c) for c in field)\nA=joinedclin.map(toCSVLine)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"79a4ece7-990e-44dc-bcd5-74ec64b4f839"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["A.take(20)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"4a5d5136-3799-4031-8223-96d2a260b702"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[39]: ['National Cancer Institute (NCI) 3218',\n 'M.D. Anderson Cancer Center 2414',\n 'Assistance Publique - Hôpitaux de Paris 2369',\n 'Mayo Clinic 2300',\n 'Merck Sharp & Dohme Corp. 2243',\n 'Assiut University 2154',\n 'Novartis Pharmaceuticals 2088',\n 'Massachusetts General Hospital 1971',\n 'Cairo University 1928',\n 'Hoffmann-La Roche 1828',\n 'National Taiwan University Hospital 1814',\n 'Eli Lilly and Company 1641',\n 'Memorial Sloan Kettering Cancer Center 1604',\n 'University of California, San Francisco 1598',\n 'National Institute of Allergy and Infectious Diseases (NIAID) 1582',\n 'Duke University 1581',\n 'Stanford University 1552',\n 'Bayer 1469',\n 'Seoul National University Hospital 1465',\n 'Washington University School of Medicine 1374']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[39]: ['National Cancer Institute (NCI) 3218',\n 'M.D. Anderson Cancer Center 2414',\n 'Assistance Publique - Hôpitaux de Paris 2369',\n 'Mayo Clinic 2300',\n 'Merck Sharp & Dohme Corp. 2243',\n 'Assiut University 2154',\n 'Novartis Pharmaceuticals 2088',\n 'Massachusetts General Hospital 1971',\n 'Cairo University 1928',\n 'Hoffmann-La Roche 1828',\n 'National Taiwan University Hospital 1814',\n 'Eli Lilly and Company 1641',\n 'Memorial Sloan Kettering Cancer Center 1604',\n 'University of California, San Francisco 1598',\n 'National Institute of Allergy and Infectious Diseases (NIAID) 1582',\n 'Duke University 1581',\n 'Stanford University 1552',\n 'Bayer 1469',\n 'Seoul National University Hospital 1465',\n 'Washington University School of Medicine 1374']"]}}],"execution_count":0},{"cell_type":"code","source":["for b in A.take(10):\n    print (b)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3d441c2c-bed0-41e7-92da-6cbd3e4e0b18"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"National Cancer Institute (NCI) 3218\nM.D. Anderson Cancer Center 2414\nAssistance Publique - Hôpitaux de Paris 2369\nMayo Clinic 2300\nMerck Sharp & Dohme Corp. 2243\nAssiut University 2154\nNovartis Pharmaceuticals 2088\nMassachusetts General Hospital 1971\nCairo University 1928\nHoffmann-La Roche 1828\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["National Cancer Institute (NCI) 3218\nM.D. Anderson Cancer Center 2414\nAssistance Publique - Hôpitaux de Paris 2369\nMayo Clinic 2300\nMerck Sharp & Dohme Corp. 2243\nAssiut University 2154\nNovartis Pharmaceuticals 2088\nMassachusetts General Hospital 1971\nCairo University 1928\nHoffmann-La Roche 1828\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["QUESTION 6"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"304c6ff2-b600-4fae-86a5-81a1f1fb392b"}}},{"cell_type":"code","source":["mymonthRDD= mysplitRDD.map(lambda t: (t[2],t[4]))\\\n.filter(lambda t: \"2021\" in t[1])\\\n.filter(lambda t: \"Completed\" in t[0])\\\n.map(lambda t: (t[1],1))\\\n.reduceByKey(lambda t, u: t+u)\\\n.map(lambda t: (t[0].split(\" \")[0],t[1]))\\\n.sortByKey(ascending=False)\nmymonthRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"53108864-a923-4402-9f33-52ae2b076417"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[41]: [('Sep', 528),\n ('Oct', 187),\n ('May', 984),\n ('Mar', 1227),\n ('Jun', 1094),\n ('Jul', 819),\n ('Jan', 1131),\n ('Feb', 934),\n ('Aug', 700),\n ('Apr', 967)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[41]: [('Sep', 528),\n ('Oct', 187),\n ('May', 984),\n ('Mar', 1227),\n ('Jun', 1094),\n ('Jul', 819),\n ('Jan', 1131),\n ('Feb', 934),\n ('Aug', 700),\n ('Apr', 967)]"]}}],"execution_count":0},{"cell_type":"code","source":["def toCSVLine(field):\n    return \" \".join(str(d) for d in field)\nmonthRDD= mymonthRDD.map(toCSVLine)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"15fc1a78-6700-404b-9158-a9fada1e8fc5"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["monthRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"0cc65881-e6c1-4e7b-9392-3f4482acb182"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[43]: ['Sep 528',\n 'Oct 187',\n 'May 984',\n 'Mar 1227',\n 'Jun 1094',\n 'Jul 819',\n 'Jan 1131',\n 'Feb 934',\n 'Aug 700',\n 'Apr 967']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[43]: ['Sep 528',\n 'Oct 187',\n 'May 984',\n 'Mar 1227',\n 'Jun 1094',\n 'Jul 819',\n 'Jan 1131',\n 'Feb 934',\n 'Aug 700',\n 'Apr 967']"]}}],"execution_count":0},{"cell_type":"code","source":["for c in monthRDD.take(10):\n    print (c)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"47c428bc-85b2-44fc-b7c9-cdf9be89c481"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Sep 528\nOct 187\nMay 984\nMar 1227\nJun 1094\nJul 819\nJan 1131\nFeb 934\nAug 700\nApr 967\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Sep 528\nOct 187\nMay 984\nMar 1227\nJun 1094\nJul 819\nJan 1131\nFeb 934\nAug 700\nApr 967\n"]}}],"execution_count":0},{"cell_type":"code","source":["import calendar\nd={i:e for e, i in enumerate (calendar.month_abbr[1:],1)}\n\n#{'Jan':1, 'Feb':2, 'Mar':3, 'Apr':4, 'May':5, 'Jun':6, 'Jul':7, 'Aug':8, 'Sep':9, 'Oct':10, 'Nov':11, 'Dec':12}\n\nmonth2RDD=mymonthRDD.sortBy(keyfunc=lambda x: d.get(x[0]))"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"26f351a6-9c8a-4114-85ee-a9a652cfb930"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["def toCSVLine(data):\n    return \" \".join(str(d) for d in data)\nmonth3RDD= month2RDD.map(toCSVLine)\n\nmonth3RDD.collect()\nfor a in  month3RDD.collect():\n    print (a)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"4e633f89-f9c2-456a-bb05-d49e87d849aa"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Jan 1131\nFeb 934\nMar 1227\nApr 967\nMay 984\nJun 1094\nJul 819\nAug 700\nSep 528\nOct 187\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Jan 1131\nFeb 934\nMar 1227\nApr 967\nMay 984\nJun 1094\nJul 819\nAug 700\nSep 528\nOct 187\n"]}}],"execution_count":0},{"cell_type":"code","source":["import matplotlib.pyplot as plt \n    # initializing the data \nx = [\"Jan\", \"Feb\", \"Mar\", \"Apr\", \"May\", \"Jun\", \"Jul\", \"Aug\", \"Sep\", \"Oct\"]\ny = [1131,934,1227,967,984,1094,819,700,528,187]\n#plotting the data \nplt.plot(x,y)\n#Adding the title plt.title(\"Completed Studies by Month\")\n#Adding the labels plt.ylabel(\"y-axis\")\nplt.xlabel(\"x-axis\")\nplt.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e82715e3-ed7c-4afa-afa6-636b9a641b10"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"markdown","source":["FURTHER ANALYSIS ON QUES 3"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"d42fe1ee-8765-496e-90bb-ef9055b4a71a"}}},{"cell_type":"code","source":["import matplotlib.pyplot as plt \nconditions = ['Carcinoma', 'Diabetes Mellitus', 'Neoplasms', 'Breast Neoplasms', 'Syndrome',]\nfigures = [13389, 11080, 9371, 8640, 8032]\nplt.figure(figsize=(55, 20))\nplt.subplot(151)\nplt.bar(conditions, figures)\nplt.title(\"Most Frequent Conditions\")\nplt.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e0b9c1cb-ed56-4c32-a007-b36d0922ab09"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"code","source":[""],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"97519d24-7030-4515-8185-f34944b7a9eb"}},"outputs":[],"execution_count":0}],"metadata":{"application/vnd.databricks.v1+notebook":{"notebookName":"NWAFULUME_RDD","dashboards":[],"notebookMetadata":{"pythonIndentUnit":4},"language":"python","widgets":{},"notebookOrigID":3274092909312700}},"nbformat":4,"nbformat_minor":0}
